Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Resolution of Cellular Heterogeneity in Human Prostate Cancers: Implications for Diagnosis and Treatment.

Maitland NJ, Frame FM, Rane JK, Erb HH, Packer JR, Archer LK, Pellacani D.

Adv Exp Med Biol. 2019;1164:207-224. doi: 10.1007/978-3-030-22254-3_16. Review.

PMID:
31576551
2.

The putative tumour suppressor protein Latexin is secreted by prostate luminal cells and is downregulated in malignancy.

Seed RI, Taurozzi AJ, Wilcock DJ, Nappo G, Erb HHH, Read ML, Gurney M, Archer LK, Ito S, Rumsby MG, Petrie JL, Clayton A, Maitland NJ, Collins AT.

Sci Rep. 2019 Mar 26;9(1):5120. doi: 10.1038/s41598-019-41379-8.

3.

The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models.

Handle F, Puhr M, Schaefer G, Lorito N, Hoefer J, Gruber M, Guggenberger F, Santer FR, Marques RB, van Weerden WM, Claessens F, Erb HHH, Culig Z.

Mol Cancer Ther. 2018 Dec;17(12):2722-2731. doi: 10.1158/1535-7163.MCT-18-0508. Epub 2018 Sep 25.

PMID:
30254184
4.

Relevance of the natural HDAC inhibitor sulforaphane as a chemopreventive agent in urologic tumors.

Juengel E, Erb HHH, Haferkamp A, Rutz J, Chun FK, Blaheta RA.

Cancer Lett. 2018 Oct 28;435:121-126. doi: 10.1016/j.canlet.2018.07.017. Epub 2018 Jul 17.

5.

Fractionated Radiation of Primary Prostate Basal Cells Results in Downplay of Interferon Stem Cell and Cell Cycle Checkpoint Signatures.

Guggenberger F, van de Werken HJG, Erb HHH, Cappellano G, Trattnig K, Handle F, Peer S, Schäfer G, Jenster G, Culig Z, Skvortsova I, Santer FR.

Eur Urol. 2018 Dec;74(6):847-849. doi: 10.1016/j.eururo.2018.06.002. Epub 2018 Jun 18. No abstract available.

PMID:
29914715
6.

Interleukin-4 induces a CD44high /CD49bhigh PC3 subpopulation with tumor-initiating characteristics.

Erb HHH, Guggenberger F, Santer FR, Culig Z.

J Cell Biochem. 2018 May;119(5):4103-4112. doi: 10.1002/jcb.26607. Epub 2018 Jan 19.

7.

The immunosuppressive cytokine interleukin-4 increases the clonogenic potential of prostate stem-like cells by activation of STAT6 signalling.

Nappo G, Handle F, Santer FR, McNeill RV, Seed RI, Collins AT, Morrone G, Culig Z, Maitland NJ, Erb HHH.

Oncogenesis. 2017 May 29;6(5):e342. doi: 10.1038/oncsis.2017.23.

8.

Inhibition of the glucocorticoid receptor results in an enhanced miR-99a/100-mediated radiation response in stem-like cells from human prostate cancers.

Rane JK, Erb HH, Nappo G, Mann VM, Simms MS, Collins AT, Visakorpi T, Maitland NJ.

Oncotarget. 2016 Aug 9;7(32):51965-51980. doi: 10.18632/oncotarget.10207.

9.

SOCS3 Modulates the Response to Enzalutamide and Is Regulated by Androgen Receptor Signaling and CpG Methylation in Prostate Cancer Cells.

Handle F, Erb HH, Luef B, Hoefer J, Dietrich D, Parson W, Kristiansen G, Santer FR, Culig Z.

Mol Cancer Res. 2016 Jun;14(6):574-85. doi: 10.1158/1541-7786.MCR-15-0495. Epub 2016 Apr 6.

10.

Therapy escape mechanisms in the malignant prostate.

Santer FR, Erb HH, McNeill RV.

Semin Cancer Biol. 2015 Dec;35:133-44. doi: 10.1016/j.semcancer.2015.08.005. Epub 2015 Aug 21. Review.

11.

Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy.

Santer FR, Erb HH, Oh SJ, Handle F, Feiersinger GE, Luef B, Bu H, Schäfer G, Ploner C, Egger M, Rane JK, Maitland NJ, Klocker H, Eder IE, Culig Z.

Oncotarget. 2015 Mar 20;6(8):6105-22.

12.

IL6 sensitizes prostate cancer to the antiproliferative effect of IFNα2 through IRF9.

Erb HH, Langlechner RV, Moser PL, Handle F, Casneuf T, Verstraeten K, Schlick B, Schäfer G, Hall B, Sasser K, Culig Z, Santer FR.

Endocr Relat Cancer. 2013 Aug 23;20(5):677-89. doi: 10.1530/ERC-13-0222. Print 2013 Oct.

13.

Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205.

Puhr M, Hoefer J, Schäfer G, Erb HH, Oh SJ, Klocker H, Heidegger I, Neuwirt H, Culig Z.

Am J Pathol. 2012 Dec;181(6):2188-201. doi: 10.1016/j.ajpath.2012.08.011. Epub 2012 Oct 3.

14.

PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21.

Hoefer J, Schäfer G, Klocker H, Erb HH, Mills IG, Hengst L, Puhr M, Culig Z.

Am J Pathol. 2012 May;180(5):2097-107. doi: 10.1016/j.ajpath.2012.01.026. Epub 2012 Mar 23.

15.

Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways.

Oh SJ, Erb HH, Hobisch A, Santer FR, Culig Z.

Endocr Relat Cancer. 2012 May 3;19(3):305-19. doi: 10.1530/ERC-11-0298. Print 2012 Jun.

16.

Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines.

Santer FR, Höschele PP, Oh SJ, Erb HH, Bouchal J, Cavarretta IT, Parson W, Meyers DJ, Cole PA, Culig Z.

Mol Cancer Ther. 2011 Sep;10(9):1644-55. doi: 10.1158/1535-7163.MCT-11-0182. Epub 2011 Jun 27.

Supplemental Content

Support Center